5月19日，南方中证全指医疗保健设备与服务ETF（159877）下跌0.04%，最新净值0.56元，连续4个交 易日下跌，区间累计跌幅1.34%。 来源：金融界 据了解，南方中证全指医疗保健设备与服务ETF成立于2021年10月，基金规模0.91亿元，成立来累计收 益率-44.22%。从持有人结构来看，截至2024年末，南方中证全指医疗保健设备与服务ETF的基金机构 持有0.16亿份，占总份额的10.95%，个人投资者持有0.92亿份，占总份额的63.55%。 公开信息显示，现任基金经理朱恒红先生:中国国籍,北京大学经济学硕士,具有基金从业资格。2016年7 月加入南方基金,历任数量化投资部助理研究员、指数投资部研究员;2019年7月12日至2020年12月25日, 任投资经理;2023年4月13日至2024年5月17日,任南方沪深300ESG基准ETF基金经理;2020年12月25日至 今,任南方策略基金经理;2021年4月23日至今,任南方中证创新药产业ETF基金经理;2021年7月16日至今, 任南方中证香港科技ETF(QDII)基金经理;2021年11月2日至今,任南方中证全指医疗保健ETF基金经 理 ...

Group 1 - The core viewpoint of the news is the performance and structure of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A, which has experienced a slight decline recently [1] - As of May 19, the fund's latest net value is 1.05 yuan, marking a continuous drop for four trading days with a cumulative decline of 1.26% [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 4.82% since inception [1] Group 2 - The fund's holder structure shows that institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, making up 8.06% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 41.48%, with major investments in companies such as Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]

STERIS (STE) Q4 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Julie Winter - Vice President of Investor Relations & Corporate CommunicationsMichael Tokich - Senior VP & CFODaniel Carestio - President, CEO & DirectorPatrick Wood - Managing DirectorMac Etoch - Senior Research Associate Conference Call Participants David Turkaly - Research AnalystMike Matson - Senior Equity Research AnalystMichael Polark - Senior Equity Research AnalystJason Bednar - Senior Research AnalystBrett Fishbin - Vi ...

Financial Data and Key Metrics Changes - First quarter revenue was $5.6 million, a decrease from $9.4 million in the same period in 2024, primarily due to the temporary suspension of sales in France and lower investments in sales and marketing [22][5] - Adjusted net operating loss narrowed by 48% to $5.9 million compared to the prior year, with gross margin expanding to 75% from 73% in the prior year and 45% in the previous quarter [5][22] - Cash and cash equivalents at the end of the first quarter were $20.4 million, providing a runway for achieving FDA approval and profitability [25][12] Business Line Data and Key Metrics Changes - Sales and marketing expenses decreased to $3.6 million from $6.1 million in the same period in 2024, driven by increased operating efficiency [23] - Research and development expenses were reduced to $2.6 million from $5.7 million, primarily due to cost reductions related to the IDISSIPPI trial [23] - General and administrative expenses decreased to $5.2 million from $6.4 million, with adjusted expenses at $3.8 million excluding one-time financing costs [24] Market Data and Key Metrics Changes - The company observed over 40% growth quarter over quarter and year over year in its B2B2C model pilot in clinics in Europe [7] - The company expects revenues to ramp as the year progresses with the expansion of the B2B2C model and enhanced sales team onboarding [8] Company Strategy and Development Direction - The company’s 2025 plan focuses on five pillars: a new commercial plan, gaining FDA approval for the Allurion balloon, achieving profitability for the ex-U.S. business, scaling the AI product platform, and resuming commercialization in France [6][7] - The company aims to combine its program with low doses of GLP-1s to create a new standard of care for obesity, targeting a sustained weight reduction of over 20% while maintaining muscle mass [16][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the efficiency of the new B2B2C model and the potential for significant shareholder value as millions of patients could be treated with the Elerion program [26][27] - The company is optimistic about completing its PMA submission to the FDA by June and is encouraged by the FDA's feedback during the pre-PMA meeting [12][39] Other Important Information - The company has resumed treating patients in France and is in the final phases of updating marketing collateral to reactivate placements [15] - The company does not expect any impact on gross margin from tariffs for the remainder of the year, as most components are manufactured in the U.S. [12][13] Q&A Session Summary Question: Trends in regional markets, especially with the new marketing strategy - Management noted that mature markets for GLP-1s are creating tailwinds, with patients seeking alternatives and the expansion of the direct sales force expected to drive revenue growth [29][30] Question: Timeline and patient enrollment for the GLP-1 trial - Enrollment is expected to begin in the latter half of this year, with a one-year follow-up and a target of at least 75 subjects across multiple sites in Europe [31][32] Question: Design of the trial arms - The trial will focus on validating previous retrospective work with a single arm prospective trial design, leveraging historical data for comparison [33][34] Question: Future gross margin expectations - Management expects margins to remain in the same range as the first quarter, with potential increases as revenues ramp up [35][36] Question: Details on the pre-PMA meeting and next steps - The FDA was receptive to alternative analyses for the control group data, which could strengthen the overall application [39][40] Question: Current adoption of the Elerion program and GLP-1s - There is organic adoption of the combination therapy in the field, with physicians integrating GLP-1s with the Allurion balloon [45][46] Question: Revenue performance cadence for 2025 - Management anticipates steady revenue increases driven by the onboarding of new sales team members and recovery in France [49][50] Question: Expected costs for the prospective study - The prospective trial is not expected to have a material impact on the budget, as existing patient flow and lower costs overseas will be leveraged [51][52] Question: Regulatory strategy regarding expanded labeling - The focus is on the commercial implications of the study, with potential long-term benefits for discussions with regulators and payers [53][54] Question: Procedure growth trends - Procedure volume is stable, with some growth in certain territories, and management expects a recovery in France in the second half of the year [57][58]

Group 1 - The pharmaceutical sector is a key focus for institutional investors, with brokers increasing their investments and research efforts in this area [1] - As of the end of Q1, 14 brokerage firms were among the top ten shareholders of 25 pharmaceutical companies, holding a total of 508 million shares valued at 4.118 billion [1] - In Q1, brokers frequently adjusted their holdings in the pharmaceutical sector, initiating positions in 10 stocks, increasing holdings in 3, and reducing holdings in 11 [1][2] Group 2 - New positions taken by brokers in Q1 included 1.162 billion for Yihe Jiaye and 1.13 billion for Borui Pharmaceutical, with significant holdings also in Jia Ying Pharmaceutical and Chuangguang Medical [2] - Brokers have been actively conducting on-site research to gather firsthand information about the pharmaceutical sector, with over 50 brokers focusing on companies like Aibo Medical and Wanjian Medical [2] - A total of 23 pharmaceutical stocks have been recommended by brokers this month, with notable mentions including Baiji Shenzhou and Heng Rui Pharmaceutical, indicating strong long-term growth prospects [3] Group 3 - The pharmaceutical sector is expected to see a recovery in profitability by 2025, with current PE valuations at historical lows, suggesting potential for excess returns compared to the broader market [3] - Analysts recommend focusing on high-growth, strong recovery, and new expectations for pharmaceutical investments in 2025, particularly in innovative drugs and medical devices [4] - Investment strategies should prioritize companies with significant product advantages and healthy balance sheets, especially those with global sales potential [4]

5月9日，塞力医疗今日收盘10.97元，下跌4.94%，最新市净率2.47，总市值20.95亿元。 股东方面，截至2025年3月31日，塞力医疗股东户数46600户，较上次增加16035户，户均持股市值35.28 万元，户均持股数量2.76万股。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-40.75%；净利润-14320949.69 元，同比-553.66%，销售毛利率23.60%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2塞力医疗-9.24-10.012.4720.95亿行业平均 36.7828.221.80107.38亿行业中值27.4324.131.3158.16亿1漱玉平民-26.84-24.692.4246.62亿3海王生 物-5.04-5.113.3661.04亿4柳药集团8.268.030.8968.68亿5九州通8.9010.440.99261.70亿6鹭燕医药 9.539.180.9831.74亿7英特集团10.6410.521.1855.27亿8国药股份11.2411.231.28224.69亿9南京医药 11.3811.750.9667.04 ...

Financial Data and Key Metrics Changes - For Q1 2025, the company reported product revenue of $43.2 million, a 13% increase year-over-year, aligning with the guidance of 10% to 15% growth [21][22] - North American product revenues increased by 22% compared to the same period last year, driven by higher platelet sales and increasing demand for IFC [22][23] - First quarter product gross profit was $25.4 million, up from $21.3 million for the same period last year, representing a 20% increase [24] - The net loss attributable to the company was $7.7 million, or $0.04 per share, compared to a net loss of $9.7 million, or $0.05 per share, for the prior year period, indicating a 20% improvement [28] Business Line Data and Key Metrics Changes - The growth in product revenue was primarily led by robust North American platelet kit sales, with increasing demand in both the U.S. and Canada [18][22] - U.S. IFC sales totaled $3 million in Q1 2025, compared to $1.9 million in Q1 2024, reflecting strong customer demand [23] - EMEA product revenue declined by 4% year-over-year, with a 1% decline on a non-GAAP basis when excluding foreign exchange impacts [22] Market Data and Key Metrics Changes - The INTERCEPT system is now used in over 40 countries, with a significant presence in North America and Europe [8] - The company anticipates continued growth in international markets, particularly in regions with emerging demand for pathogen-reduced blood products [18][72] Company Strategy and Development Direction - The company aims to expand its platelet market share in the U.S. and improve IFC supply to meet growing customer demand [9][20] - The phased global launch of the INT200 device is expected to enhance the usability and efficiency of the system, supporting future geographic expansion [8][9] - The company remains focused on securing global regulatory approvals for its INTERCEPT product portfolio to improve blood safety and availability [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating geopolitical and macroeconomic uncertainties, emphasizing the compelling value proposition of INTERCEPT [16][17] - The company is optimistic about achieving positive non-GAAP adjusted EBITDA for the full year 2025, despite potential impacts from tariffs [29][30] - Management highlighted the importance of customer feedback and real-world experience in driving growth and validating the technology [72][75] Other Important Information - The company ended Q1 2025 with $80.9 million in cash and cash equivalents, a slight increase from $80.5 million at the end of 2024 [29] - Cash used from operations was minimal at $800,000, primarily tied to investments in working capital [30] Q&A Session Summary Question: Can you provide details on the 22% growth in North American product revenue in Q1? - Management noted that growth was driven by underlying demand in the U.S. franchise, with significant contributions from both platelet and IFC sales [35][38] Question: What are the next steps regarding the CE Mark application for the INTERCEPT red blood cell system? - Management indicated that TUV is conducting a clinical review, and they are optimistic about the application due to strong prior communications and a solid submission [43][45] Question: How is the EMEA business performing, particularly in France? - Management confirmed that the French platelet market remains stable, contributing positively to overall growth, with plans to initiate activity on the plasma side [48][50] Question: What are the plans to increase production capacity for IFC? - Management explained that several blood center production partners have received biologic license application approvals, allowing them to ramp up manufacturing to meet growing demand [51][53] Question: Can you discuss the assumptions in your guidance for the year? - Management clarified that the guidance includes anticipated revenue from the INT200 device and assumes a ramp-up in IFC production throughout the year [56][60]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-023 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 根据中国证监会发布的《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》和深 圳证券交易所颁布的《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第1 号——主板上市公司规范运作》、《深圳证券交易所上市公司自律监管指南第2号——公告格式》等有 关规定，深圳市尚荣医疗股份有限公司（以下简称"公司"或"本公司"），深圳市尚荣医疗股份有限公司 （以下简称"公司"或"本公司"）董事会编制了截至2024年度募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 根据相关制度，本公司于2019年2月28日与北京银行股份有限公司深圳分行、兴业银行股份有限公司深 圳龙岗支行、中国民生银行股份有限公司深圳上步支行、平安银行股份有限公司深圳分行、中国工商银 行股份有限公司深圳东门支行及保荐机构东兴证券股份有限公司签署《募集资金三方监管协议》。对募 集资金的使用实行严格的审批手 ...

和讯财经研究院发布《2025年中国科创新锐力量榜》，榜单列出了今年中国科创板上市公司45岁以下（80后）的青年领导者，并根据上市公司2025年 一季度末市值（2025-3-21）进行排序。 4 4 位科创企业领导者进入新锐力量榜， 平均年龄42岁，男性占比88.64%， 研究生学历占70.45%，博士研究生占25%， 47.73%来自北上广深一线城市， 行业分布上主要来自 信息技术40.91%、工业制造 29.55 %、 医疗保健 22.73 %三大行业 ， 相比科创板整体而言， 新锐力量女性占比更高、 高教育背景更普遍、 来自一线城市比例更高、 行业分布更 集 中 ， 展现出中国科技创新领导力量新趋势。 和A财经研究院 发现中国新力量 Hexun Financial Research 2025科创新锐力量 和讯财经研究院发布《2025科创新锐领导力量TOP 44》，榜单 列出了今年中国科创板上市公司45岁以下（80后）的 青年领导者,并根据上市公司2025年一季度末 市值(2025-3-31)进行排序。 01 ambricon 临大口 |寒武纪董事长,创始人 | | 核心技术人员 毛 科创板市值排名:2/5 ...

Report Industry Investment Rating No relevant content provided. Core Viewpoints of the Report - The sustainability of the rebound remains to be confirmed, and it is advisable to embrace gold. The current primary contradiction is not employment and inflation but tariff policies. After a significant valuation correction, the PE has become reasonable but not undervalued. Whether corporate earnings expectations will be adjusted due to tariffs depends on the ongoing Q1 earnings reports, and whether there will be an earnings correction in the future requires further confirmation. Although the 90 - day delay in tariff implementation has provided some relief to the market, uncertainties still persist. Therefore, a defensive approach is the main strategy, and it is recommended to invest in gold, which has a hedging property [2][3]. Summary According to Relevant Catalogs Macro Data - As of the week ending April 5, the number of initial jobless claims was 223,000, in line with the forecast, and the four - week moving average remained unchanged, indicating overall stability in the employment market. In March, the CPI was 2.4% year - on - year, better than the expected 2.5%; month - on - month, it was - 0.1%, better than the expected 0.1%. The core CPI was 2.8% year - on - year, better than the expected 3%; month - on - month, it was 0.1%, better than the expected 0.3%. In April, the preliminary reading of the 1 - year inflation expectation in the University of Michigan survey soared to 6.7%, a new high since 1981, higher than the expected 5.2% and the previous value of 5%; the preliminary reading of the 5 - year inflation expectation was 4.4%, higher than the expected 4.3% and the previous value of 4.1%. The preliminary reading of the consumer confidence index was 50.8, significantly lower than the expected 53.5 and the previous value of 57 [3][8][9]. Market Sentiment - The US Economic Policy Uncertainty Index (EPU) reached 678.44 points, with a weekly moving average of 676.57 points, a new high since 2018, mainly due to the inconsistent tariff policies of the Trump administration, which disrupted market expectations and caused significant market fluctuations. The retail sentiment indicator compiled by the American Association of Individual Investors (AAII) showed that 58.9% of US retail investors were bearish on the stock market, while 28.5% were bullish, with a bull - to - bear ratio of 0.48, an improvement from the previous value (0.35), but pessimism still prevailed. The Fear and Greed Index remained in the 'Extreme Fear' zone for three consecutive weeks, closing at 13 points; among its seven sub - indicators, only 'Junk Bond Demand' showed 'Fear', while the other six showed 'Extreme Fear' [3][16][17]. Global Market - The global equity market rose 3.4% last week, with developed markets (4.4%) outperforming emerging markets (- 3.9%), and the US stock market led the global market. Gold continued its upward trend, rising 7.2% last week, and it has been rising across all observed time frames. Bitcoin was weak, with a weekly increase of - 0.3% [3][22]. Industry Performance - Among the 36 secondary industries in the US stock market, 31 rose and 5 fell. Industries such as national defense and military, non - ferrous metals, and semiconductors had relatively large increases. The absolute values of the top three gainers were much larger than those of the bottom three. Eleven secondary industries outperformed the S&P 500 index (5.7%) [24]. S&P 500 Component Stocks - Among the S&P 500 component stocks, 372 stocks rose last week, accounting for 74%, and the number of rising stocks increased significantly compared to the previous week. The top - ranked stocks in terms of gains were NEWMONT, BROADCOM, CONSTELLATION ENERGY, PALANTIR TECHNOLOGIES, GE VERNOVA, etc. Among the 20 core component stocks, Broadcom led with a weekly increase of 24.4%, while ExxonMobil performed the worst with a weekly decrease of - 1.2% [26][28]. Volume and Price Indicators - The strong secondary industries were semiconductors, software services, medical equipment and services, etc. The estimated average daily capital intensity of the semiconductor industry last week was approximately $325.4 billion, ranking first. Last week, the estimated capital inflows were relatively concentrated in stocks such as NVIDIA, TESLA, and PALANTIR TECHNOLOGIES [30][32]. Market Valuation - In the past week, the static PE of the S&P 500 was 24.3 times, the Bloomberg Forward PE rose slightly from 19 times to 19.8 times, an increase of 4.3%; the Bloomberg - predicted EPS decreased slightly from $268 to $266, a decrease of 0.5% [34]. Gold Industry - As of April 10, 2025, the price of the gold industry was in the range of 10.7x P/E to 19.3x P/E, at a relatively low level; the P/E in Q2 2025 is expected to rebound significantly, and the earnings per share (EPS) in Q2 2025 is expected to rebound significantly. In the short term, the gold price has shown obvious fluctuations due to tariff policies. In the long term, factors such as the expectation of more severe stagflation in the US after the tariff increase, global economic and political uncertainties, and the gold - buying demand of emerging market central banks may support the gold price [37][41].